

Applicants: Novak et al.

Serial No.: 10/659,684

Filed: September 10, 2003

For: CYTOKINE ZALPHA11 LIGAND

---

The Office Action sets forth a restriction requirement under 35 USC §121. Applicants were requested to elect one of four designated groups as briefly noted below:

I. Claims 1-11, drawn to a protein, classified in class 530, subclass 350.

II. Claims 12-30, drawn to a method of treating cancer or method of stimulating an immune response in a mammal with melanoma by administering an effective amount of a polypeptide, classified in class 514, subclass 12.

III. Claims 31-40 and 45-46, drawn to a method of stimulating an immune response in a mammal with melanoma by administering an effective amount of a polynucleotide and pharmaceutical composition, classified in class 514, subclass 44.

IV. Claims 41-44 and 47, drawn to a nucleic acid encoding a polypeptide, a vector and a host cell, classified in class 435, subclass 69.1.

In response to the Requirement for Restriction Election, Applicants elect Group I, drawn to a protein, classified in class 530, subclass 350.

Applicants submit herewith a Preliminary Amendment to update the Reference to Related Applications section of the Application. Early consideration and allowance of the pending claims under examination are respectfully requested. If the Examiner believes that a telephone interview would expedite prosecution of the above-identified patent application, please call the undersigned at (206) 442-6672.

Respectfully Submitted,



Deborah A. Sawislak  
Registration No. 37,438

Enclosures:

Amendment Fee Transmittal (in duplicate)  
Preliminary Amendment  
Supplemental Information Disclosure Statement  
PTO-1449  
11 References

Customer No. 10117  
ZymoGenetics, Inc.  
1201 Eastlake Avenue East  
Seattle, Washington 98102